The most compelling opportunity is Hims & Hers Health (HIMS), which is considered a strong buy following its recent strategic acquisition of Australian telehealth company Eucalyptus. HIMS is viewed as a long-term winner aiming to become a dominant global consumer health platform by disrupting traditional healthcare with its AI-driven model. Similarly, NVIDIA (NVDA) is seen as severely undervalued, as the market has not fully priced in its massive potential in the AI sector. In contrast, legacy businesses like Walgreens (WBA) face an existential threat from these online disruptors and should be avoided. Other major tech stocks like Google (GOOGL) are seen as fairly valued, while Apple (AAPL) is considered a little expensive at current levels.

Hims & Hers Health, Inc. (HIMS)

• The speaker is extremely bullish on HIMS, viewing it as a company that is creating a new, technology-driven form of healthcare that is poised for massive growth.
• Eucalyptus Acquisition: The primary focus of the discussion is the recent acquisition of Australian telehealth company Eucalyptus.
  • Eucalyptus has $450 million in Annual Recurring Revenue (ARR) and is experiencing triple-digit growth.
  • The company is described as being near profitability.
  • HIMS acquired it for only $240 million in upfront cash, with the rest of the deal structured as seller financing. The speaker calls this a "fire sale" price.
  • The acquisition expands HIMS's international footprint, notably entering the Japanese market.
  • It also adds new service lines that HIMS can cross-pollinate into its other markets, including:
    • Kin: A brand focused on fertility.
    • Compounding dermatology: Similar to what the company Oddity is doing.
    • A weight-loss platform focused on the drug Ally.
• Investment Thesis:
  • Big Tech Playbook: HIMS is following the playbook of major tech companies to become the dominant global consumer health platform.
  • AI & Data Flywheel: The company is building an AI-driven platform. With the acquisition, it will have roughly 3 million customers, creating a massive dataset to improve its AI recommendations, which in turn attracts more customers. The ultimate goal is AI-designed, one-to-one custom medications.
  • Disruption: HIMS is a major disruptor to several industries:
    • The traditional "sick care" industry and health insurance model.
    • Physical pharmacies (like Walgreens) and medical office real estate.
  • Valuation: The speaker believes the stock is "so cheap" and that the market fundamentally misunderstands its potential. They note that even though the stock price is three times higher than their initial purchase, the valuation is now lower, indicating massive business growth.

Takeaways

• The speaker presents a strong bullish case for HIMS, framing the Eucalyptus acquisition as a brilliant strategic move that was executed at an exceptionally low price.
• The long-term investment thesis is based on HIMS becoming a global, AI-powered healthcare platform that disrupts the entire traditional healthcare system.
• The current stock price is seen as a significant buying opportunity, as the speaker believes Wall Street and the market have failed to grasp the company's innovative model and long-term potential.

NVIDIA (NVDA)

• The speaker mentions NVIDIA as a prime example of a company that Wall Street misunderstands because it "hates innovation" and "doesn't get AI."
• They express a strong belief that the company is severely undervalued, stating, "I cannot possibly imagine how undervalued NVIDIA is."
• The speaker references their own spreadsheet model, which gives NVIDIA a score of 0.5, implying it is an extremely strong buy according to their personal metrics.

Takeaways

• The speaker's sentiment is extremely bullish.
• The core insight is that the market has not correctly priced in NVIDIA's dominance and potential in the field of Artificial Intelligence. This perceived misunderstanding presents a significant investment opportunity.

Google (GOOGL)

• Google was mentioned briefly in a valuation comparison with other major tech companies.
• The speaker's assessment is that the stock is "fairly valued."

Takeaways

• The speaker holds a neutral view on Google's current stock price.
• This suggests that, in the speaker's opinion, the stock is neither a compelling buy nor an urgent sell at its current valuation.

Apple (AAPL)

• Apple was mentioned briefly in a valuation comparison with other major tech companies.
• The speaker's assessment is that the stock is "a little expensive."

Takeaways

• The speaker holds a slightly cautious or bearish view on Apple's current valuation.
• This suggests the stock may be overvalued and might not present a good entry point for new investors at this time.

Walgreens (WBA)

• Walgreens is used as an example of an outdated, legacy business model that is vulnerable to disruption.
• The speaker notes that physical pharmacies are "on the decline" and will eventually "be gone," directly threatened by online healthcare platforms like HIMS.
• The speaker expresses surprise that people are still investing in companies like Walgreens given these disruptive trends.

Takeaways

• The speaker's sentiment is clearly bearish.
• The insight is that Walgreens's business model, which relies on a large network of physical pharmacy stores, faces an existential threat from the shift to online, tech-enabled healthcare.